




Agilent to acquire Resolution Bioscience

March 2, 2021



Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information about Agilent's and Resolution Bio's products and capabilities, the growth of its business and the market, strategic goals, payment for certain milestones, the effect of the acquisition on earnings, revenue projections, return on invested capital and the timing of completion of the acquisition) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, the adverse impacts of and risks posed by the COVID-19 pandemic, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the fiscal quarter ended January 31, 2021.

The company assumes no obligation to update the information in this presentation.

Fast growing technologies expand Cancer Dx TAM⁽¹⁾

RESOLUTION's powerful NGS based technology platform adds Liquid Biopsy based molecular diagnostics capabilities to Agilent's Pathology and Companion Dx franchise.



Serves Biopharma companies through application of its **powerful NGS based technology platform** that has been optimized for **liquid biopsy**.

NGS platform can be tailored to BioPharma's individual pre-clinical and clinical needs and has been **designed to enable** both a **centralized CLIA test** service format and **distributable kit** format.

NGS technologies which **complement Agilent's existing IHC assay capabilities**

(1) TAM – Total Addressable Market (2) CDx – Companion diagnostics



Strategic Fit with Agilent

Fast-growth technology complements Agilent's leading cancer diagnostics and precision medicine portfolio.

Opportunity to **innovate and accelerate** biomarker discovery and development of CDx⁽²⁾ tests using both genomic and protein profile; and to **democratize cancer testing** through distributable kits

Strong **cultural and technology fit**, and leverages Agilent's expertise and pharma relationships.

Transaction Highlights

Financial Profile

Purchase Price :	\$550M upfront, plus up to \$145M milestone payments dependent on product regulatory milestones and revenue targets
Expected Close :	Fiscal Q2, FY21
Revenue :	2020 (Calendar): \$35M; 2021 Projection: \$50M - \$55M
EPS :	Modestly dilutive in FY21 and FY22 (<1%), improving thereafter
ROIC⁽¹⁾ :	Expect to achieve high-single-digits in 5 years

Addressable Market

TAM profile :	NGS BioPharma CDx Services, Therapy Selection and Monitoring markets growing at 25%+ expected to reach \$3B by 2025
Agilent Business :	Will be part of Agilent's Diagnostics and Genomics Group

\$3B

Projected TAM⁽²⁾ in 2025

25%+

Market Growth

40%+

Resolution's last 3-year revenue CAGR⁽³⁾

(1) ROIC – Return on Invested Capital (2) TAM – Total Addressable Market (3) CAGR – Compound Annual Growth Rate